ZACKS INVESTMENT MANAGEMENT
Position in ALNY — Alnylam Pharmaceuticals, Inc.
CIK 1086483
Chicago, IL
Position in ALNY
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$2,533,769
-$65,875 QoQ
Shares Held
8,417
+7.1% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#297
of 784 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ALNY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ZACKS INVESTMENT MANAGEMENT holds $33,185,332 across 8 Biotechnology names. ALNY ranks #3 (7.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
55,052 | $27,345,979 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
32,627 | $2,553,715 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
This page
|
8,417 | $2,533,769 | |
| 4 | AUPH |
Aurinia Pharmaceuticals Inc.
|
36,687 | $622,578 | |
| 5 | LCTX |
Lineage Cell Therapeutics, Inc.
|
42,084 | $55,130 | |
| 6 | AGEN |
Agenus Inc
|
10,550 | $32,283 | |
| 7 | INO |
Inovio Pharmaceuticals, Inc.
|
26,435 | $29,078 | |
| 8 | GERN |
Geron Corp
|
10,000 | $12,800 |
All Filings in ALNY
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,533,769 | 8,417 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $2,599,644 | 7,857 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $4,774,981 | 12,008 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $5,428,224 | 11,904 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $3,890,579 | 11,931 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $6,011,185 | 22,262 | Shares | Sole | 2025-05-14 | |
| No filing history on record for this holder in this stock. | ||||||